Stifel Reiterates Buy Rating, $35 Price Target on Kinnate Biopharma (KNTE) Ahead of the Upcoming KIN-2787 Readouts May 13, 2022 06:05AM
William Blair Reiterates Outperform Rating on Kinnate Biopharma (KNTE), Sees Potential for Significant Upside in Shares Mar 29, 2022 11:16AM
Stifel Reiterates Buy Rating, $35 PT on Kinnate Biopharma (KNTE), "Remain Optimistic into KIN-2787 Monotherapy Data" Mar 29, 2022 05:58AM
Stifel Reiterates Kinnate Biopharma (KNTE) at Buy, Optimistic That KIN-287 Can Improve Efficacy Feb 11, 2022 09:05AM
Kinnate Biopharma (KNTE) Attractive into Two Separate Upcoming Catalysts - Stifel Jan 7, 2022 06:31AM